Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
about
Dispersion of Nanoparticles in Different Media Importantly Determines the Composition of Their Protein Corona.BIO-NANO INTERFACE AND ENVIRONMENT: A CRITICAL REVIEW.Protein Corona: Impact of Lymph Versus Blood in a Complex In Vitro Environment.Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.Binding of human serum albumin to PEGylated liposomes: insights into binding numbers and dynamics by fluorescence correlation spectroscopy.Triphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria.Plasma protein adsorption and biological identity of systemically administered nanoparticles.Polymeric nanomicelles: a potential hazard for the cardiovascular system?Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment.Nanomedicine: Evolution of the nanoparticle corona.Impact of ConcanavalinA affinity in the intracellular fate of Protein Corona on Glucosamine Au nanoparticles.Exploitation of nanoparticle–protein corona for emerging therapeutic and diagnostic applicationsThe Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery
P2860
Q36239570-5C365198-5A7F-46A2-B9B3-9885EFFD300DQ38653826-F20DC1C5-CCCB-47FF-A306-9A5152893966Q38674654-326B48F6-4A70-4997-9949-1094598E6DB0Q38697472-B351CD89-3D61-49D8-A517-6D7BC3C14AB5Q39164444-3E6A3ED5-7BD0-4824-8D4E-45C254370442Q42255827-FD5162F7-3152-4F6C-B744-E0D4754474E8Q47570893-732300C3-C64C-402E-8023-770DE21BBB6FQ50869509-9ADDCDC0-9102-4C22-99CB-D79845F24174Q52707854-87A796B2-A40F-4A29-B1A9-9DD53773B2AEQ53785476-6823A037-E4C6-42F9-AA5E-99DA9911EEE9Q55374417-94D8E088-F615-411A-94AB-36BC5F7E2D52Q57966772-CAC1C629-EA56-42A1-B23F-5FA38AEC65DBQ58803479-B6EC7CAC-173D-4896-9D20-9F2B212808CF
P2860
Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Time-evolution of in vivo prot ...... rubicin (DOXIL) nanoparticles.
@en
Time-evolution of in vivo prot ...... EGylated liposomal doxorubicin
@nl
type
label
Time-evolution of in vivo prot ...... rubicin (DOXIL) nanoparticles.
@en
Time-evolution of in vivo prot ...... EGylated liposomal doxorubicin
@nl
prefLabel
Time-evolution of in vivo prot ...... rubicin (DOXIL) nanoparticles.
@en
Time-evolution of in vivo prot ...... EGylated liposomal doxorubicin
@nl
P2860
P356
P1433
P1476
Time-evolution of in vivo prot ...... rubicin (DOXIL) nanoparticles.
@en
P2093
Kostas Kostarelos
P2860
P304
P356
10.1039/C5NR09158F
P407
P577
2016-03-10T00:00:00Z